AstraZeneca Pharma India (NSE:ASTRAZEN) Moat Score: 0/10 (As of Jul. 01, 2026)


NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
92 GF Score
Price ₹8,176.50
GF Value ₹10,897.00
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Moat Score?

AstraZeneca Pharma India has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

AstraZeneca Pharma India has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AstraZeneca Pharma India might have No Moat - No discernible moat.

AstraZeneca Pharma India  (NSE:ASTRAZEN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AstraZeneca Pharma India Moat Score Related Terms

NSE:ASTRAZEN
92GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,176.50 is trading 25% below its estimated GF Value™ of ₹10,897.00. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • Moat Score: 0
  • GF Value™: ₹10,897.00 vs. price of ₹8,176.50 (25% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score

Get the complete analysis for NSE:ASTRAZEN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,176.50
Price
₹10,897.00
GF Value